Cannabis and Canabidinoids on the Inflammatory Bowel Diseases: Going Beyond Misuse

Inflammatory bowel diseases (IBD) are characterized by a chronic and recurrent gastrointestinal condition, including mainly ulcerative colitis (UC) and Crohn’s disease (CD). Cannabis sativa (CS) is widely used for medicinal, recreational, and religious purposes. The most studied compound of CS is tetrahydrocannabinol (THC) and cannabidiol (CBD). Besides many relevant therapeutic roles such as anti-inflammatory and antioxidant properties, there is still much controversy about the consumption of this plant since the misuse can lead to serious health problems. Because of these reasons, the aim of this review is to investigate the effects of CS on the treatment of UC and CD. The literature search was performed in PubMed/Medline, PMC, EMBASE, and Cochrane databases. The use of CS leads to the improvement of UC and CD scores and quality of life. The medical use of CS is on the rise. Although the literature shows relevant antioxidant and anti-inflammatory effects that could improve UC and CD scores, it is still not possible to establish a treatment criterion since the studies have no standardization regarding the variety and part of the plant that is used, route of administration and doses. Therefore, we suggest caution in the use of CS in the therapeutic approach of IBD until clinical trials with standardization and a relevant number of patients are performed.

Download Full-text

Effect of joint transition visits on quality of life in adolescents with inflammatory bowel diseases: a protocol for a prospective, randomised, multicentre, controlled trial (TRANS-IBD)

BMJ Open ◽

10.1136/bmjopen-2020-038410 ◽

2020 ◽

Vol 10 (10) ◽

pp. e038410

Author(s):

Adrienn Erős ◽

Dóra Dohos ◽

Gábor Veres ◽

András Tárnok ◽

Áron Vincze ◽

...

Keyword(s):

Quality Of Life ◽

Inflammatory Bowel Diseases ◽

Transition Period ◽

Treatment Plan ◽

Number Of Patients ◽

Bowel Diseases ◽

Inflammatory Bowel ◽

The Impact ◽

Paediatric Gastroenterologist

IntroductionInflammatory bowel diseases (IBD) are among the most common chronic illnesses diagnosed in childhood. Transition from paediatric to adult care is a crucial phase. The implementation of joint visits during the transition period in IBD is widely recommended, however, strong evidence supporting their benefit is still missing. In this trial, we aim to prove the superiority of joint visits compared with usual care in improving transition outcomes of adolescents with IBD.Methods and analysisThis is a randomised controlled two-arm multicentre trial. A minimum of 160 adolescents with IBD aged between 16.75 and 17 years will be recruited from Hungarian tertiary IBD centres. After randomisation, eligible subjects in the intervention arm attend a total of four joint visits with adult and paediatric gastroenterologist between the ages of 17 and 18. In the control arm, adolescents meet only the paediatric gastroenterologist, but there is a balanced consultation between the two gastroenterologist regarding the patient’s treatment plan. Patients in both groups receive the same training and education, the only determinative difference between the two arms is the presence of the adult gastroenterologist at the joint visits. Data will be collected at inclusion, at transfer and 12 months post-transfer. Primary outcome is the change in health-related quality of life measured with the IMPACT-III questionnaire at 1 year after transfer. Secondary outcomes include the number of patients not lost to follow-up, healthcare utilisation, disease activity, medication adherence, self-efficacy, transition readiness and patient’s satisfaction. To compare the results of the two patient groups, two-sample T-test and Mann-Whitney test will be applied.Ethics and disseminationThe Scientific and Research Ethics Committee of the Hungarian Medical Research Council approved this study (50457-2/2019/EKU). Findings will be disseminated at conferences and in medical journals.Trial registration numberNCT04290156.

Download Full-text

Does Infliximab Short Infusion have a Beneficial Impact on the Quality of Life in Patients with Inflammatory Bowel Diseases? A Single Centre Prospective Evaluation

Journal of Gastrointestinal and Liver Diseases ◽

10.15403/jgld.2014.1121.242.tezz ◽

2015 ◽

Vol 24 (2) ◽

pp. 165-170 ◽

Cited By ~ 8

Author(s):

Mariabeatrice Principi ◽

Giuseppe Losurdo ◽

Rosa Federica La Fortezza ◽

Pasquale Lopolito ◽

Rosa Lovero ◽

...

Keyword(s):

Quality Of Life ◽

Inflammatory Bowel Diseases ◽

Adverse Reactions ◽

Severe Disease ◽

Sexual Life ◽

Necrosis Factor Alpha ◽

Short Infusion ◽

Bowel Diseases ◽

Inflammatory Bowel

Background & Aims: Infliximab (IFX) is an anti-tumor necrosis factor alpha agent used in inflammatory bowel diseases (IBD) therapy. Usually, it is administered over a 2-hour intravenous infusion. However, shortening the infusion duration to 1 hour has proved to be feasible and safe. In the present study we evaluated whether shortening the IFX infusion could affect the patients' quality of life (QoL) compared to the standard protocol.Methods: Subjects affected by IBD receiving IFX were prospectively recruited. The main criterion to shorten the infusion was the absence of IFX-related adverse reactions during the previous three 2-h infusions. For each patient, demographic, clinical and anthropometric data were collected. A questionnaire investigating their overall/job/social/sexual QoL was administered. Ordinal regression was performed with odds ratios (OR) for significant independent variables.Results: Eighty-one patients were included (46 with ulcerative colitis - UC, 35 with Crohn's disease - CD). Sixteen received the 2-h infusion due to previous adverse reactions, and the remaining 65 underwent the 1-h schedule. Shortening the infusion to 1 hour determined a better QoL (OR=0.626). However, the QoL was negatively influenced by age (OR=1.023), female sex (OR=2.04) and severe disease activity (OR=7.242). One-hour IFX infusion induced a better outcome on work (OR=0.588) and social (OR=0.643) QoL. Long-standing disease was correlated with a slightly better sexual QoL (OR=0.93). Conversely, older age (OR=1.046), severe clinical score (OR=15.579), use of other immunomodulators (OR=3.693) and perianal CD (OR=3.265) were related to an unsatisfactory sexual life. The total number of infusions (OR=0.891), proctitis (OR=0.062) or pancolitis (OR=0.1) minimized the perception of infusion-related side effects.Conclusion: The 1-h short infusion improves overall, social and job QoL, so that, when indicated, it should be recommended.

Download Full-text

THE RELATIONSHIP OF QUALITY OF LIFE AND CLINICAL CHARACTERISTICS IN INFLAMMATORY BOWEL DISEASES IN CHILDREN

PEDIATRIA Journal named after G N SPERANSKY ◽

10.24110/0031-403x-2019-98-6-31-36 ◽

2019 ◽

Vol 98 (6) ◽

pp. 31-36 ◽

Cited By ~ 1

Author(s):

A.R. Tagirova ◽

◽

I.V. Sichinava ◽

Keyword(s):

Quality Of Life ◽

Inflammatory Bowel Diseases ◽

Clinical Characteristics ◽

Bowel Diseases ◽

Inflammatory Bowel ◽

Relationship Of ◽

The Relationship

Download Full-text

The Effect of Joint Transition Visits on Quality of Life in Inflammatory Bowel Diseases (TRANS-IBD)

Case Medical Research ◽

10.31525/ct1-nct04290156 ◽

2020 ◽

Author(s):

Keyword(s):

Quality Of Life ◽

Inflammatory Bowel Diseases ◽

Bowel Diseases ◽

Inflammatory Bowel

Download Full-text

Quality-of-life estimation by Polish and American inflammatory bowel diseases patients – pilot study

Gastroenterology Review ◽

10.5114/pg.2011.25995 ◽

2011 ◽

Vol 6 ◽

pp. 388-400

Author(s):

Ludwika Jakubowska-Burek ◽

Izabella Warmuz-Stangierska ◽

Elżbieta Kaczmarek ◽

Marcin A. Kucharski ◽

Emilia Marcinkowska ◽

...

Keyword(s):

Quality Of Life ◽

Pilot Study ◽

Inflammatory Bowel Diseases ◽

Life Estimation ◽

Bowel Diseases ◽

Inflammatory Bowel

Download Full-text

Quality of Life Considering Patients with Chronic Inflammatory Bowel Diseases - Natural and Parenteral Nutrition

Polish Journal of Surgery ◽

10.2478/pjs-2014-0073 ◽

2014 ◽

Vol 86 (9) ◽

Cited By ~ 1

Author(s):

Aneta Raczkowska ◽

Michał Ławiński ◽

Aleksandra Gradowska ◽

Urszula Zielińska-Borkowska

Keyword(s):

Quality Of Life ◽

Ulcerative Colitis ◽

Crohn’S Disease ◽

Crohn's Disease ◽

Parenteral Nutrition ◽

Inflammatory Bowel Diseases ◽

Nutritional Therapy ◽

Bowel Diseases ◽

Inflammatory Bowel

AbstractOne of the elements of treatment considering inflammatory bowel diseases is nutritional therapy. The duration of the above-mentioned depends on the prevalence of such symptoms as fever, bowel move-ments, length of the functioning gastrointestinal tract, stoma and intestinal fistula presence. Nutritional therapy is an essential element of successful treatment alongside pharmacological, surgical, and biological therapy, as well as other methods. Crohn's disease and ulcerative colitis considered as chronic diseases, lead towards physical and biopsychosocial disability, being responsible for the reduction in the quality of life.was to determine the quality of life after surgical procedures in case of patients diagnosed with Crohn's disease and ulcerative colitis, subjected to natural and parenteral nutrition.The study group comprised 52 patients from the Department of Gastroen-terology, Military Medical Institute, and Department of Surgery and Clinical Nutrition, Clinical Hospital in Warsaw. The study was performed between October, 2011 and April, 2012. The World Health Organization Quality of Life Instrument - Bref (WHOQOL-BREF) questionnaire was used to deter-mine the patients’ quality of life.A lower quality of life was observed in case of patients subjected to parenteral nutrition, poor education, disease symptoms exacerbation, in the majority-rural inhabitants. The quality of life does not depend on gender, type of disease, family status, and additional medical care.

Download Full-text